Adial Pharmaceuticals posts promising update on alcohol disorder drug
- Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug. What it means for Adial Pharmaceuticals stock The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients.
- 04/10/2024
|
Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?
- Adial Pharmaceuticals (NASDAQ: ADIL ) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. This peer review focuses on Phase 3 clinical trial results for AD04.
- 04/10/2024
|
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
- Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial
- 04/10/2024
|
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
- Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
- 04/02/2024
|
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
- CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275397). The gross proceeds to the Company from the exercise of the warrants are expected to be $3,530,500, prior to deducting placement agent fees and estimated offering expenses.
- 03/01/2024
|
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
- New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder
- 02/28/2024
|
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
- CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024. Cary Claiborne, Chief Executive Officer of Adial, is scheduled to present on Tuesday, February 20 at 11:30 a.m.
- 02/15/2024
|
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
- Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence
- 02/13/2024
|
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
- Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board Member Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board Member
- 01/18/2024
|
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
- CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that on December 16, 2023, it received the final development cost reimbursement payment of $350,000 from Adovate, LLC under the terms of the final asset purchase agreement (the “FAA”) executed with Adovate for purchase of the assets and business of the Company's wholly owned subsidiary, Purnovate, Inc. Under the agreement, the Company is also eligible to receive up to approximately $11 million in development and approval milestones for each compound (up to $33 million in total development and approval milestones for the first three compounds alone), as well as a total of $50 million in additional commercial milestones, for a total consideration of up to $83 million with potential milestone payments on additional compounds. Additionally, the Company will receive a low, single-digit royalty and acquired a 15% equity stake in Adovate. The FAA also provides for anti-dilution protection from future Adovate equity raises in order to maintain at least 15% ownership in Adovate. The anti-dilution protection expires upon Adovate receiving $4,000,000 in cumulative funding.
- 12/20/2023
|
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
- CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq today that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. Nasdaq will continue to monitor the Company's ongoing compliance with the stockholders' equity requirement and, if at the time of its next periodic report the Company does not evidence compliance, it may be subject to delisting.
- 11/29/2023
|
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules; Extends Cash Runway into Q4 2024 CHARLOTTESVILLE, Va., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2023.
- 11/14/2023
|
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
- CHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Chief Medical Officer of Adial, Bankole Johnson, D.Sc., M.D., and Key Opinion Leaders Jonathan Chick, M.D., Hannu Alho, M.D., and Icro Maremmani M.D., will be presenting at The Annual International Society of Addiction Medicine Conference taking place November 2-4, 2023, in Marrakesh, Morocco.
- 10/31/2023
|
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
- Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 10/30/2023
|
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar
- Experts agree that there are benefits to reductions in drinking, supporting the ongoing development of non-abstinence-based therapies to treat alcohol use disorder Experts agree that there are benefits to reductions in drinking, supporting the ongoing development of non-abstinence-based therapies to treat alcohol use disorder
- 10/25/2023
|
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has closed its previously announced private placement offering for the purchase and sale of an aggregate of 1,418,440 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,418,440 shares of common stock and series B warrants to purchase up to 1,418,440 shares of common stock, at a purchase price of $2.82 per share of common stock (or common stock equivalent in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules.
- 10/24/2023
|
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,418,440 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,418,440 shares of common stock and series B warrants to purchase up to 1,418,440 shares of common stock, at a purchase price of $2.82 per share of common stock (or common stock equivalent in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The offering is expected to close on or about October 24, 2023, subject to the satisfaction of customary closing conditions.
- 10/20/2023
|
Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th
- CHARLOTTESVILLE, VA / ACCESSWIRE / October 19, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Fall Foliage MicroCap Rodeo Conference that will be held virtually Tuesday, October 24th through Friday, October 27th, 2023. Cary Claiborne, CEO of Adial Pharmaceuticals, is scheduled to present on Wednesday, October 25th, at 10:30 a.m.
- 10/19/2023
|
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
- 09/05/2023
|
Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th
- CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced today that it will be presenting at the Jefferies 2023 Global Healthcare Conference being held June 7-9, 2023, at the Marriott Marquis in New York, NY.
- 06/01/2023
|
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
- Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
- 04/04/2023
|
10 Hot Penny Stocks Under $1 To Watch This Week
- Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/09/2023
|
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
- Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
- 10/19/2022
|
Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher
- Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 09/01/2022
|
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
- Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
- 08/26/2022
|
Adial Clinical Trial: A Fluff Or A Win?
- Onward Phase III Clinical Trial of Adial Pharmaceutical's AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy drinking days, the primary end-points were not achieved in.
- 08/22/2022
|
What's Going On With Adial Pharmaceuticals Stock Today?
- Shares of small-cap penny stock Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares are trading about 20.5% lower at $1.46 per share Wednesday morning. The company announced topline results for its Onward Phase 3 trial for AD04 in patients with Alcohol Use Disorder.
- 07/20/2022
|
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
- Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET
- 07/18/2022
|
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- Adial Pharmaceuticals, Inc. (ADIL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 06/14/2022
|
5 Winning Stocks Backed by the Overlooked Rising P/E Strategy
- Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.
- 04/06/2022
|
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?
- Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.
- 01/12/2022
|
Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference
- CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.
- 01/10/2022
|
Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate
- Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs.
- 10/21/2021
|
Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021
- CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually this week, October 5 - 8, 2021. William Stilley, Chief Executive Officer and President of Adial Pharmaceuticals, will present at the conference.
- 10/05/2021
|
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
- CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on recently issued patents for the use of Adial's lead asset, AD04, for the treatment of both Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). AD04 is currently being evaluated in the Company's ONWARD trial, a Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with AUD, which is being conducted in seven countries.
- 08/10/2021
|
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
- Data merits further testing for pain reduction as a possible alternative to opioids
- 07/14/2021
|
Adial Pharmaceuticals Provides Regulatory and Development Update
- CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has received correspondence related to its request for Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate, AD04, for the treatment of Alcohol Use Disorder (AUD) in pediatric patients and adult patients with Alcoholic Liver Disease (ALD) with select polymorphisms of the serotonin transporter and receptor genes. While AD04 is being developed and undergoing a pivotal Phase 3 trial to treat any adult with AUD with the targeted genetics, Adial believes AD04 holds the potential to effectively and safely treat AUD patients that are adolescents or have ALD.
- 06/24/2021
|
Top 10 Biotech Penny Stocks to Watch in July 2021
- Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/22/2021
|
ADIL Stock Price Increases Over 30% Pre-Market: Why It Happened
- The stock price of Adial Pharmaceuticals Inc (NASDAQ: ADIL) increased by over 30% pre-market. This is why it happened.
- 06/22/2021
|
Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder
- CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer, and Dr. Bankole Johnson, Chief Medical Officer, have been featured on multiple news broadcasts nationwide regarding the ‘Second Pandemic of Addiction' arising from the COVID-19 pandemic.
- 05/18/2021
|
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
- CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 2021.
- 02/26/2021
|
Adial to File Fast Track Application for AD04 with the FDA
- CHARLOTTESVILLE, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be filing an application for “Fast Track” with the U.S. Food and Drug Administration (FDA) for its lead drug candidate, AD04, which is a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes.
- 02/23/2021
|
Adial Pharmaceuticals to Present at 23rd Annual ICR Conference
- CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals has been invited to present a Company overview at the 23rd Annual ICR Conference on Thursday, January 14, 2021 at 3:15pm-3:55pm Eastern Time. A live webcast of the Company's presentation will be available on the Investors section of the Company's website (https://www.adialpharma.com/).
- 01/11/2021
|
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
- CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced receipt of a Notice of Allowance for its third U.S. patent relating to the use of AD04 for the treatment of opioid use disorder (OUD). The patent covers the use of the Company's lead product, AD04, as a treatment of Opioid Use Disorder in patients with a specific genetic biomarker in the serotonin transporter gene.
- 01/11/2021
|
Adial Pharmaceuticals : Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests | MarketScreener
|
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests | MarketScreener
|
Adial Pharmaceuticals: Opportunity Knocks For Micro Cap Targeting Multi-Billion Alcohol Use Disorder Market (NASDAQ:ADIL)
- Adial is a tiny microcap attempting to convert an approved nausea and sickness treatment, Ondansetran, into a treatment for alcohol use disorder.
- 10/17/2020
|
Why Adial's Stock Is Trading Lower Today
- Adial Pharmaceuticals (NASDAQ: ADIL) shares are trading lower on Wednesday, potentially selling off after surging on Tuesday following FDA emergency use authorization for the...
- 09/30/2020
|
Why Adial Pharmaceuticals Is Trading Higher Today
- Adial Pharmaceuticals (NASDAQ: ADIL) shares are trading higher on Tuesday after the company announced the FDA has issued an emergency use authorization for the company's...
- 09/29/2020
|
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits
- CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2020 / Adial Pharmaceuticals, Inc.
- 08/06/2020
|
LD Micro Announces Preliminary List of Presenters for the LD 500
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Maxim Group Remains a Buy on Adial Pharmaceuticals (ADIL) - Markets
- Maxim Group analyst Jason McCarthy reiterated a Buy rating on Adial Pharmaceuticals (ADIL – Research Report) yesterday and set a
- 07/31/2020
|
Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call
- Developments to be Shared by Dr.
- 07/28/2020
|
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder
- EMA Agreement paves the way for a marketing authorization in Europe after Phase 3CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc.
- 07/22/2020
|
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia
- CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approvals in Sweden and Estonia to commence the Company's landmark ONWARD™ pivotal Phase 3 clinical trial to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. The Swedish Medical Products Agency and Swedish Ethical Review Authority have provided approval for ONWARD™ to commence in Sweden; and the Estonian State Agency of Medicines and Ethics Review Committee overseeing human trials granted approval to commence ONWARD™ in Estonia.
- 07/06/2020
|
Today's Exchange Rate News 26.06.2020: Pound Tracks Sideways, Euro Weak, Dollar Steady As US Statistics Mixed
- Today's Exchange Rate News 26.06.2020: Pound Tracks Sideways, Euro Weak, Dollar Steady as US Statistics Mixed
- 06/26/2020
|
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland | | IT Business Net
- Polish clinical sites initiated less than two weeks after regulatory approval CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a
- 06/25/2020
|
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland
- CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. "We are pleased to announce we were able to begin the trial less than two weeks after we received approval from Poland's Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and the relevant regional Polish ethics committees overseeing the trial," commented William Stilley, Chief Executive Officer of Adial Pharmaceuticals.
- 06/25/2020
|
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia | | IT Business Net
- ONWARD™ trial progresses with the opening of sites in Latvia CHARLOTTESVILLE, VA / ACCESSWIRE / June 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage b
- 06/17/2020
|
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia
- CHARLOTTESVILLE, VA / ACCESSWIRE / June 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has opened clinical trial sites and is recruiting trial subjects in Latvia after receiving all necessary approvals to commence the landmark ONWARD™ pivotal Phase 3 clinical trial in Latvia, including from the State Agency of Medicines of the Republic of Latvia and the Latvian Central Ethics Committee. The ONWARD™ trial is investigating Adial's lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes.
- 06/17/2020
|
AUD/USD reversal extends to 0.6833 lows against a firmer US dollar | Forex Crunch
- AUD/USD reversal from 0.6975 extends to intra-day lows at 0.6833. The US dollar loses appreciates with equity markets off highs as market mood sours.
- 06/16/2020
|
Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering | | IT Business Net
- CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the developme
- 06/15/2020
|
Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering
- CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its lead drug candidate, AD04, for the treatment of Alcohol Use Disorder, today announced the closing on June 11,2020 of its previously announced registered direct offering of 2,820,000 shares of its common stock at a purchase price of $1.85 per share for gross proceeds of $5,217,000 priced at-the-market under Nasdaq rules. In a concurrent private placement, Adial also issued warrants to purchase 2,115,000 shares of common stock, which warrants are immediately exercisable, will expire 5 years from the date of issuance and will have an exercise price of $2.00 per share of common stock.
- 06/15/2020
|
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland
- CHARLOTTESVILLE, VA / ACCESSWIRE / June 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received all necessary approvals to commence its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. This includes the receipt of approvals from both the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and the relevant regional Polish Ethics Committees overseeing the trial.
- 06/11/2020
|
Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits
- CHARLOTTESVILLE, VA / ACCESSWIRE / June 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received an initial firm order for the purchase of 1,000 Rapid Result COVID-19 antibody test kits. The customer intends to utilize the test kits for understanding exposure to the virus in the City of Phoenix, Arizona and surrounding communities and to advance efforts to protect the health and safety of frontline workers.
- 06/10/2020
|
Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market
- CHARLOTTESVILLE, VA / ACCESSWIRE / June 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its lead drug candidate, AD04, for the treatment of Alcohol Use Disorder, today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $5.2 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stock in a concurrent private placement. The combined purchase price for one share of common stock and a warrant to purchase 0.75 shares of common stock will be $1.85.
- 06/09/2020
|
Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests
- Antibody Testing Available for Landmark ONWARD (TM) Pivotal Phase 3 Trial Participants BioLab Sciences Grants Adial Exclusive Rights to Sell and Distribute Rapid Result COVID-19 Antibody Tests to Designated ...
- 06/08/2020
|
Adial Pharmaceuticals Appoints Dr. Jack Reich to Board of Directors
- CHARLOTTESVILLE, VA / ACCESSWIRE / May 28, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment of Dr. Jack Reich to the Board of Directors. Dr. Reich will serve on the Audit Committee as well as the Nominations and Corporate Governance Committee.
- 05/28/2020
|
FXA: Australian Dollar Is A Once-In-A-Decade Buy
- Australian dollar ETF (FXA) has been in a decade-long bear market and recently plummeted below 2009 lows along with AUD/USD. Australia's low debt-to-GDP and rec
- 05/11/2020
|
Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress
- CHARLOTTESVILLE, VA / ACCESSWIRE / May 4, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced ...
- 05/04/2020
|
Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility
- CHARLOTTESVILLE, VA / ACCESSWIRE / April 23, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, ...
- 04/23/2020
|
Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial
- CHARLOTTESVILLE, VA / ACCESSWIRE / April 16, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced that the functionality of its proprietary companion diagnostic genetic test has been verified as clinically effective through its utilization in the landmark ONWARD™ pivotal Phase 3 clinical trial of the Company's lead drug candidate, ultra-low dose ondansetron (AD04), for the treatment of Alcohol Use Disorder (AUD). The Company expects to expand the use of the genetic test into clinical trials of AD04 in the future for the treatment of other indications such as Opioid Use Disorder (OUD) and is working to establish testing capacity in the United States for future studies.
- 04/16/2020
|
Adial Pharmaceuticals Issued Second Patent Covering AD04 as a Treatment for Opioid Use Disorder
- CHARLOTTESVILLE, VA / ACCESSWIRE / April 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that U.S. Patent Number 10,619,209, titled "Serotonin Transporter Gene and Treatment of Opioid-Related Disorders" issued on April 14, 2020. This patent covers the treatment of Opioid Use Disorder by administering the Company's investigational new drug product, AD04, an antagonist of the serotonin-3 receptor (5-HT3), to patients with the LL and TT genotypes, which may be identified by Adial's proprietary genetic test. The gene responsible for encoding the serotonin transporter (SERT), SLC6A4, located on the chromosome 17q11.1-q12, is the only known gene encoding the serotonin transporter and has a functional polymorphism at the 5'-regulatory promoter region, which results in two forms, long (L) or short (S).
- 04/15/2020
|
Adial Pharmaceuticals Provides Update on ONWARD(TM) Phase 3 Pivotal Trial
- CHARLOTTESVILLE, VA / ACCESSWIRE / April 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its landmark ONWARD™ Phase 3 pivotal trial of its lead drug candidate, AD04, in genetically identified subjects for the treatment of Alcohol Use Disorder (AUD). The number of in-clinic visits per subject has been reduced from 19 to 8.
- 04/09/2020
|
Will Adial Pharmaceuticals (NASDAQ:ADIL) Spend Its Cash Wisely?
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 03/29/2020
|
Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder
- CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2020 / Adial Pharmaceuticals, Inc. (ADIL)(ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it received an Issue Notification for the issuance of a patent by the United States Patent and Trademark Office (USPTO) for the treatment of Opioid Use Disorder (OUD) with its lead drug candidate, AD04, in people that are positive for select genotypes identified using the Company's propriety companion genetic test. Including the patent term adjustment provided in the Issue Notification, the patent is expected to provide commercial exclusivity for AD04 until September 2031, plus potential Hatch-Waxman extensions.
- 03/26/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19
- CHARLOTTESVILLE, VA / ACCESSWIRE / March 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that, effective immediately, the Company is modifying its pivotal Phase 3 clinical trial of the Company's lead drug candidate, AD04, for the treatment of alcohol use disorder (AUD) in genetically targeted patients. In order to better protect subjects enrolled in the Phase 3 clinical trial during the COVID-19 pandemic, the Company is in the process of modifying its protocol to reduce the number of in-person visits to clinical sites and replace certain visits with tele-medicine behavioral treatments and assessments. European regulators have encouraged sponsors of clinical trials to take action to reduce travel and potential exposure of study subjects and have indicated receptivity to modifications that achieve this end.
- 03/17/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
- 02/28/2020
|
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria
- CHARLOTTESVILLE, VA / ACCESSWIRE / February 19, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approval to commence its Phase 3 study to investigate AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in Bulgaria in persons with certain target genotypes related to the serotonin transporter and receptor genes. This includes receiving approvals from both the Bulgarian Drug Agency and the Bulgarian Ethics Committee for Clinical Trials overseeing the study. "Bulgaria is expected be an important country in our Phase 3 trial of AD04 in biomarker-positive study participants," stated William Stilley, Chief Executive Officer of Adial Pharmaceuticals.
- 02/19/2020
|
Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat
- CHARLOTTESVILLE, VA / ACCESSWIRE / February 14, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, is pleased to announce that the Company's CEO, William Stilley, has been selected as a luncheon keynote speaker for the 2020 Wall Street Conference and Retreat to be held in West Palm Beach, Florida on February 19-20. The Company recently announced it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD).
- 02/14/2020
|
Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder
- CHARLOTTESVILLE, VA / ACCESSWIRE / February 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The trial has initially started in Finland, where Adial previously announced it had received approval to commence the trial. Adial has filed clinical trial applications (CTAs) to also conduct the trial in each of these countries where additional trial sites will be initiated on a country-by-country basis following each CTA approval.
- 02/06/2020
|
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland
- CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received favorable opinions from the Finnish Medicines Agency (FIMEA) and National Committee on Medical Research Ethics (TUKIJA) to commence its Phase 3 study to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). "Finland is the first of seven European countries in which we plan to open clinical sites as we conduct our AD04 Phase 3 trial in AUD subjects with certain target genotypes related to the serotonin transporter and receptor genes, which appeared to correlate to response to treatment with AD04 in the Phase 2b clinical trial," commented Monika Rogozinska, Chief Development Officer of Adial Pharmaceuticals.
- 01/09/2020
|
Need To Know: Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Insiders Have Been Buying Shares
- We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- 12/30/2019
|
Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries
- CHARLOTTESVILLE, VA / ACCESSWIRE / December 19, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has submitted Clinical Trial Applications (CTAs) to commence its first Phase 3 trial in Finland, Estonia, Latvia, Poland, Bulgaria, and Croatia. This follows the Company's recent filing of a CTA to also commence its first Phase 3 trial in Sweden, as previously announced. The planned Phase 3 trial will test AD04 as a genetically-targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD).
- 12/19/2019
|
Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker
- CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a patent by the United States Patent and Trademark Office (USPTO), titled: "Serotonin Transporter Gene and Treatment of Alcoholism." This patent addresses a method of treating alcohol use disorder (AUD) in patients with a specific genetic biomarker in the serotonin transporter gene by administering the Company's investigational new drug product, AD04, a 5-HT3 antagonist, to patients with the TT genotype.
- 12/16/2019
|
JNUG, TVIX, VCYT, AAXN, IIN, WTW
- Stocks Analysis by Harry Boxer covering: Intuitive Surgical Inc, Axon Enterprise Inc, IntriCon Corporation, WW International Inc. Read Harry Boxer's latest article on Investing.com
- 01/04/2019
|
